Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Navellier & Associates Inc.

Navellier & Associates Inc. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 15.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,163 shares of the biopharmaceutical company’s stock after buying an additional 1,869 shares during the period. Navellier & Associates Inc.’s holdings in Catalyst Pharmaceuticals were worth $296,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $65,000. KBC Group NV raised its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $134,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $151,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 79,500 shares of company stock valued at $1,754,140. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $21.63 on Monday. The company has a 50-day simple moving average of $22.25 and a 200-day simple moving average of $21.37. Catalyst Pharmaceuticals, Inc. has a one year low of $13.49 and a one year high of $24.64. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of 18.33, a PEG ratio of 3.31 and a beta of 0.80.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on CPRX shares. StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Robert W. Baird started coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price objective on the stock. Bank of America restated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, Truist Financial raised their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.25.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.